Market Selloff

Novo Nordisk’s Obesity Drug Trial Results Sparks Sharp Market Selloff

Business Pen
[stock_market_widget type=”card” template=”basic2″ assets=”NVO” realtime=”true” api=”yahoo-finance”] Novo Nordisk (NYSE: NVO) has spent years building its reputation around treatments for diabetes and obesity, so investors have...

Subscribe to Newsletter